Savara, Inc. is a pharmaceutical company based in the United States that specializes in rare respiratory diseases. The company is currently developing an inhaled treatment called molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis (aPAP). With a medium risk rating score of 25.8, Savara, Inc. focuses on sustainability and governance practices in the pharmaceutical industry.